Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease

BACKGROUND: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been documented with significantly reduction in LDL cholesterol levels and cardiovascular events. However, evidence regarding the impact of PCSK9 inhibitors on coronary calcification is limited. METHODS: Eligible patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Fei, Li, Yue Ping, Ma, Xiao Teng, Wang, Zhi Jian, Shi, Dong Mei, Zhou, Yu Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120536/
https://www.ncbi.nlm.nih.gov/pubmed/35600486
http://dx.doi.org/10.3389/fcvm.2022.907662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120536/
https://www.ncbi.nlm.nih.gov/pubmed/35600486
http://dx.doi.org/10.3389/fcvm.2022.907662

Ejemplares similares